DwightE.Heron,MDPrincipalInvestigator

BarbKlewien,BSProjectDirector

OurTeam

  DwightE.Heron,MD‐PI  HeatherJones,MD–Co‐investigator  SusanRakfal,MD–Co‐investigator  BarbaraKlewien,BS–ProjectDirector  MicheleWagner,RN–ClinicalResearchCoordinator

SummaryofROCOGI

  Nocostextensionpending  Closeoutinprogress  Trialsaccruals:118  Navigationprogramssustainedin3communities  TELESYNERGY™fullyintegratedin3sites

  Tumorboards(NewCastle/McKeesport)  Mentorcommunication(McKeesport)  Patientconsultation(Somerset)

  Outreachtonearly47,000individuals  Publications–14papersinpeerreviewedjournals  Presentations–21oral&poster

PlansforROCOGII

  Patient‐centeredinformeddecisioncoachimplementation

  Implementpopulationappropriatetrials  Implementscreeningdocumentationtool  SustainabilityplansbeyondROCOGII

TypicalUPMCMcKeesportPatientScreenedforTrials

  Age65orolder(63%)  Caucasian(80%)  AfricanAmerican(17%)  Notaccrueddueto:

  Noavailabletrial(54%)  Latestagediseaseatpresentationprevalentincommunity

  Clinicaltrial(s)criteriatoorestrictive(22%)

InformedDecisionCoachStudy

  Designedasclinicaltrial  PendingIRBapproval  Evaluates

  Patientsatisfactionwithdecision Willeducation(diseasespecific)increaseaccrualtoclinicaltrials

  Differencebetweensatisfactionwithdecisioninclinicaltrialvsnonclinicaltrialparticipants

AddressingPopulation‐AppropriateTrials

  Investigator‐initiatedbreasttrial  HypofractionatedRadiationTherapyfortheElderlyBreastCancer(H.Jones,PI)

  Ongoingassessmentofavailabletrials  Evaluationofmostappropriate&availabletrials

AccrualsbyDiseaseSite

Disease Site Trials Open % open trials Patients Accrued

% Patients Accrued

Brain 4 8% 14 13%

Breast 11 23% 32 30%

GI 10 21% 20 19%

Head & Neck 8 17% 15 14%

Lung/Thoracic 12 25% 21 20%

Prostate/Urolog 3 6% 5 5%

48 100% 107 100%